CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors
- 1 September 2001
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (17) , 1347-1353
- https://doi.org/10.1038/sj.gt.3301515
Abstract
Intravenous administration of adenoviral vectors results mostly in hepatocyte transduction and subsequent hepatotoxicity. Because hepatocytes express high levels of the primary adenovirus receptor CAR, untargeting hepatocytes requires CAR-binding ablation. The amino acid residues of the viral fiber responsible for CAR-binding are known. We have constructed a mutant adenoviral vector unable to bind CAR and studied vector biodistribution and hepatotoxicity after intravenous administration. In contrast to a vector with wild-type fiber, the infectivity of the CAR-ablated vector is greatly reduced and not susceptible to inhibition with wild-type knob. Biodistribution and hepatotoxicity are, however, not affected by CAR-binding ablation. A possible explanation could be related to an increased blood persistence detected for the CAR-ablated vectors combined with their residual infectivity through other receptors.Keywords
This publication has 27 references indexed in Scilit:
- Blood clearance rates of adenovirus type 5 in miceJournal of General Virology, 2000
- Targeting of adenoviral vectors through a bispecific single-chain antibodyCancer Gene Therapy, 2000
- Heparan Sulfate Glycosaminoglycans Are Involved in Adenovirus Type 5 and 2-Host Cell InteractionsVirology, 2000
- Evaluation of the Biodistribution, Persistence, Toxicity, and Potential of Germ-Line Transmission of a Replication-Competent Human Adenovirus Following Intraprostatic Administration in the MouseMolecular Therapy, 2000
- Targeting adenovirusGene Therapy, 2000
- Identification of a Conserved Receptor-Binding Site on the Fiber Proteins of CAR-Recognizing AdenoviridaeScience, 1999
- Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriersGene Therapy, 1999
- A system for the propagation of adenoviral vectors with genetically modified receptor specificitiesNature Biotechnology, 1999
- Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in VivoHuman Gene Therapy, 1999
- Adenovirus type 5 fiber knob binds to MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cellsThe EMBO Journal, 1997